Back to mobile site

Mizuho Reiterates Neutral Rating on Apellis Pharmaceuticals (APLS)

January 28, 2025 12:16 PM EST Send to a Friend
Mizuho analyst Graig Suvannavejh reiterated a Neutral rating and $30.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS)The analyst comments "Yesterday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login